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Saliva is an important compound produced by the salivary glands and performs numerous functions.
Hyposalivation (dry mouth syndrome) is a deleterious condition often resulting from radiotherapy for patients with
head and neck cancer, Sjogren’s Syndrome, or as a side effect of certain medications. Hyposalivation negatively
affects speaking, mastication, and swallowing in afflicted patients, greatly reducing their quality of life. Current
treatments for this pathology include modifying lifestyle, synthetic saliva supplementation, and the utilization of
salivary gland stimulants and sialagogues. However, many of these treatments do not address the underlying issues
and others are pervaded by numerous side effects. In order to address the shortcomings related to current
treatment modalities, many groups have diverted their attention to utilizing tissue engineering and regenerative
medicine approaches. Tissue engineering is defined as the application of life sciences and materials engineering
toward the development of tissue substitutes that are capable of mimicking the structure and function of their
natural analogues within the body. The general underlying strategy behind the development of tissue engineered
organ substitutes is the utilization of a combination of cells, biomaterials, and biochemical cues intended to
recreate the natural organ environment. The purpose of this review is to highlight current bioengineering
approaches for salivary gland tissue engineering and the adult stem cell sources used for this purpose.
Additionally, future considerations in regard to salivary gland tissue engineering strategies are discussed.
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Saliva is a watery substance produced by the salivary
glands. It consists of mucus, various electrolytes, glyco-
proteins, enzymes, and antibacterial compounds such as
lysozyme and IgA [1]. In relation to its excretory com-
position, saliva performs many important functions such
as breaking down starch into maltose for digestion, aid-
ing in basic oral functions (e.g. speaking, mastication,
and swallowing), and protecting against microbial re-
lated pathologies such as dental caries and periodontitis.
Thus, any dysfunction or cessation to saliva production
is a significant clinical concern. Hyposalivation, which is
a characteristic of xerostomia (dry mouth syndrome),
can significantly reduce the quality of life for afflicted
patients [2,3]. Major causes of hyposalivation include
Sjögren’s Syndrome (SS) [4], γ-irradiation therapy for* Correspondence: hwjun@uab.edu
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unless otherwise stated.patients with head and neck cancer [5], and results of
side effects from various medications and ectodermal
dysplasias [6-8].
Current treatments for hyposalivation include symp-
tom management, lifestyle changes, synthetic saliva sup-
plementation, and the utilization of salivary gland
stimulants and sialagogues (e.g., the muscarinic receptor
agonists pilocarpine and cevimeline) which stimulate sal-
ivary secretion from residual acinar cells [9,10]. Salivary
gland stimulation via supplementation of cytokines or
small molecules such as pilocarpine or amifostine to in-
crease the secretion of saliva is the most commonly used
treatment. However, this only treats surface level symp-
toms, provides temporary relief, and is plagued by mul-
tiple multiple side effects such as excessive sweating,
chills, dizziness, excessive tearing, flushing, voice change,
stuffy nose, tremor, nervousness, and diarrhea [11,12].
Thus, development of an alternative treatment to pro-
vide a long-term and effective solution solution is im-
perative [13]. In order to address the limits associated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vestigated various regenerative medicine strategies utiliz-
ing different stem cell sources to engineer artificial
salivary tissues that can mitigate the effects of xerosto-
mia and hyposalivation.
Tissue engineering is defined as the application of life sci-
ences and materials engineering toward the development of
tissue substitutes that are capable of mimicking the struc-
ture and function of their natural analogues within the body
[14]. The general underlying strategy behind the develop-
ment of tissue engineered organ substitutes is the utilization
of a combination of cells, biomaterials, and biochemical cues
intended to recreate the natural organ environment. This
article is intended to provide a review of the most current
approaches to utilizing stem cells and bioengineering princi-
ples for the purpose of salivary tissue regeneration.
Review
Anatomy of the salivary glands
Within the body, there are three main sources of saliva
production: The parotid gland, the submandibular gland,
and the sublingual gland. Additionally, there are 800–100
minor salivary glands throughout the oral cavity that pro-
duce a small amount of saliva, although, this amount is
considerably less than the three major salivary organs [15].
Each of the salivary glands is located in various locations
throughout the oral cavity in humans [16]. The parotid
glands are the largest of the salivary glands and are located
at the back of the mouth adjacent to the mandibular
ramus. The submandibular glands are a pair of glands lo-
cated superior to the diagastric muscles and below the
jaws, juxtaposed and perpendicular to the mandibular
ramus. The saliva produced by the submandibular glands
accounts for roughly 70% of the saliva present within the
oral cavity, despite the fact that they are smaller than the
parotid glands. The sublingual glands are a pair of glands
located anterior to the submandibular glands and inferior
to the tongue and are responsible for the production of
around 5% of the saliva present within the oral cavity.
Each of the glands is encapsulated within connective tis-
sue and arranged into lobules.
In terms of their growth and development, each of
these organs are formed from two different layers of the
three primary embryonic germ layers [17]. The subman-
dibular and sublingual glands are derived from the endo-
derm, whereas the parotid gland is of ectodermal origin.
The parotid gland produces a serous, watery secretion
while the submandibular and sublingual glands produce
secretions that contain mucus as well [16].
The salivary glands of most mammals are made up of
three main cell types: serous producing acinar cells, mu-
cous producing acinar cells, and myoepithelial cells [16].
Serous producing acinar cells have a pyramidal morph-
ology and are joined together to form spheroidal shapeswhile mucous producing acinar cells are cuboidal in
shape and group together to form tubules. Myoepithelial
cells are located near the ductal openings and serve to
contract the ducts in order to squeeze out salivary secre-
tions (Figure 1) [18].
The effects of radiotherapy on salivary gland cells are
confounding. Theoretically, saliva producing acinar cells
are not predicted to be radiation sensitive due to the fact
that they are post-mitotic in nature [19]. However, des-
pite this, irradiated salivary glands exhibit severe, early
losses in saliva production [20]. In this regard, it is dis-
puted as to whether radiation induced hyposalivation is
a result of apoptosis or dysfunction resulting from radi-
ation induced damage to the membranes of acinar cells
[18,21-24]. During the later phases of radiotherapy in-
duced hyposalivation, functionally mature acinar cells
cease their proliferation and are not replaced. It is sug-
gested that the population responsible for replacing ma-
ture acinar cells, known as salivary gland progenitor cells
(SSPCs), lose their regenerative capability as a result of ra-
diation induced damage as well [20,25,26]. Due to this
fact, much effort has been expended towards assessing
various stem cell sources and materials to serve as poten-
tial replacements for SSPCs damaged during radiotherapy.
The purpose of this review is to highlight current bio-
engineering approaches for salivary gland tissue engin-
eering and the adult stem cell sources used for this
purpose. Some of the most currently studied adult de-
rived stem cell populations for the purpose of salivary
gland regeneration include salivary gland-derived stem
cells (SGSCs), mesenchymal stem cells (MSCs), and hu-
man amnion epithelial stem cells (hAECs).Salivary gland-derived stem cells
Since adult stem cells are generally restricted to cell line-
ages of the body part of origin, researchers have attempted
to use stem cells derived from salivary glands (SGSCs) to
reduce hyposalivation and restore natural function [17].
Thus far, several approaches have been taken towards iso-
lating and characterizing these stem cells. Some groups
have sequestered cells from the parotid gland [27], the
submandibular gland [28], a combination of both glands
[29], and by co-culture [30].
Stem cells from the human parotid gland, removed via
lateral parotidectomy, have been isolated and characterized
in vitro [27]. Flow cytometry analysis showed that these
stem cells were strongly positive for classic MSC markers
(CD13, CD29, CD44, and CD90) and negative for key
hematopoietic stem cell (HSC) markers (CD34, CD45).
These SG-derived stem cells further displayed MSC-like
characteristics by demonstrating the ability for adipo-
genic, osteogenic, and chondrogenic differentiation when
grown in their respective induction media.
Figure 1 Schematic representation of a generic salivary gland showing component cell types and theorized stem and progenitor cell
locations. Reproduced with permission from: [18].
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parotid and submandibular glands were revealed to have
a certain capacity for in vivo recovery of salivary gland
function in radiation-damaged rat salivary glands [29].
Prior in vitro experiments confirmed that the SGSCs
expressed MSC markers (CD44, CD49f, CD90, and
CD105), excluded HSC markers (CD34, CD45), differen-
tiated into MSC lineages, and could differentiate into
amylase-expressing cells. Radiation-induced hyposaliva-
tion in rats was generated using an x-ray irradiator and
human SGSCs (hSGSCs) were transplanted into the
glands. After 60 days, the average saliva flow rate of the
irradiation-damaged, hSGSC-treated group was twice
that of the PBS-treated, irradiation-damaged group but
was still lower than the undamaged group. Treatment
with hSGSC was also quantified by measuring the rat
body weight over time; the average body weight of
hSGSC-treated rats was slightly increased in comparison
to the PBS-treated rats.
By using a floating sphere culture, further in vitro
characterization of submandibular-derived SGSCs revealed
cellular expression of Sca-1, c-Kit, and Musahsi-1 [28]. Im-
munohistochemical staining over a 10 day period was per-
formed to analyze the origination and development of cellspheres. Initial H&E, Periodic Acid Schiff (PAS), CK7,
and CK14 staining showed that cultured spheres con-
tained acinar and ductal cells. Interestingly, acinar cells
mostly disappeared by the third day but reappeared
within the existing ductal spheres by the fifth day in cul-
ture. By day ten, acinar cells dominated sphere compos-
ition and amylase expression, quantified using RT-PCR,
increased almost 25-fold after 20 days (Figure 2).
The in vitro results suggest that these sphere-forming
cells originate from salivary gland ducts and are able to
differentiate into amylase-producing, acinar-like cells.
To analyze the stem cell characteristics of these spheres
(now termed salispheres), common stem cell markers
(Sca-1, c-Kit, and Musashi-1) were fluorescently labeled
and visualized in culture. Sca-1 and c-Kit expression was
seen in excretory duct cells but not acinar cells. Results
from the H&E/PAS staining were confirmed by the
fluorescent microscopy, which indicated a peak Sca-1
expression at 5 days.
Intraglandular transplantation of 3-day cultured sali-
spheres into irradiated mice resulted in the formation of
ductal structures near the injection site. There was an
increase in acinar cell surface area in salisphere-treated
mice compared to the untreated group. Ninety days after
Figure 2 Differentiation of salisphere into acinar cells. (A) Amylase expressing cells (AC) in submandibular gland tissue (Tissue) were also
present at the onset of culture (A-D0), and were visualized in the sphere at the onset of day 5 (A-D5), whereas granulae-containing spheres
appeared in culture at later time-points (A-D10). Antibody labeling is shown in brown, nuclei in blue. Scale bar = 50 mm. (D = duct cells, AC =
acinar cells, D0–3– 5–10 represent days in culture). (B) Real time RT-PCR confirmed the enhanced expression of amylase during in vitro culturing
and differentiation. Error bars represent SEM (N = 2). Amylase mRNA expression levels at 2 days of culture were normalized to one. Reproduced
with permission from: [28].
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was higher than the untreated counterparts and corre-
lated strongly with acinar surface area. After purifying
salispheres to a c-Kit+ population, cells were capable of
differentiating into acinar cells in vitro and transplant-
ation of a small number of cells (300–1000 per gland)
improved saliva production in 69% of irradiated mice
in vivo, after 120 days.
However, a major limitation for SGSC therapy in the
treatment of radiation-induced hyposalivation is the diffi-
culty with isolating autologous stem cells from a severely
injured gland. To overcome this barrier, a co-culture sys-
tem of mouse embryonic stem cells (mESCs) and human
SG fibroblasts was developed to facilitate differentiation of
mESCs to SGSCs [30]. After 1 week in co-culture, a sig-
nificant change in cell morphology was found and RT-
PCR results showed a sudden appearance of amylase and
bFGF. These GFP-expressing SG cells were transplanted
into normal mice submandibular glands and histology was
performed after 1 month. H&E and PAS staining of
SGSC-treated mice showed normal formation of ductal
and acinar structures. Fluorescent microscopy of the
GFP-positive donor cells qualitatively confirmed the
cells’ ability to integrate into the existing tissue. Even
though this method is not confined by the need for au-
tologous stem cells from a radiation-damaged gland, it
is limited by the ethical concerns surrounding embry-
onic stem cells and their lack of availability in clinical
settings.Bone marrow mesenchymal stem cells (MSCs)
Mesenchymal stem cells (MSCs) are multipotent stem
cells capable of differentiating into many cell types, in-
cluding chondrocytes, adipocytes, osteoblasts, acinar
cells, and salivary epithelial cells [31-34]. Their potential
to repair damaged tissues, anti-inflammatory effects, and
low immunogenicity make MSCs strong candidates for
both experimental investigations in vitro and in vivo as
well as clinical treatment of various diseases [31-35].
Therefore, MSCs were investigated for regeneration and
functional restoration of the salivary gland.
MSC implantation and Sjögren’s syndrome
Two studies investigated the role of MSCs as a therapeutic
option for treatment of Sjögren’s syndrome (SS), a chronic
autoimmune disorder that results in exocrine gland in-
flammation, impaired salivary function, and lymphocytic
infiltrates within the salivary glands [31,35]. Khalili et al.
[35] used NOD mice with a Sjögren’s syndrome-like dis-
ease to investigate the effect of MSCs in reducing lympho-
cytic infiltrates in the salivary gland and restoring salivary
function (Figure 3). They found that intravenous injection
of MSCs reduced lymphocytic infiltrate and inflammation
in the salivary gland compared to untreated controls, in-
cluding a 10-fold decrease in the inflammatory cytokine
TNF-α. MSC injection also preserved the saliva flow rate
over the 14 week post-treatment period; moreover, when
MSCs were administered in conjunction with complete
Freund’s adjuvant (CFA), the salivary gland regenerative
Figure 3 Lymphocytic infiltrates in salivary glands of NOD mice. A–E: H&E staining showing lymphocytic infiltration size (shown by yellow
line and arrows) in NOD that were: untreated (A), CFA-treated (B), MSC + CFA (C), MSC (D). In 2 of the 5 NOD mice transplanted with MSCs only,
no lymphocytic infiltrates were noted (E). Scale bar: 140 um for all images. (F): Salivary flow rates (SFRs) of NOD mice. SFRs in MSC + CFA (black
circle; n = 10) and MSC (black square; n = 5) groups did not decrease during the follow-up period (22 wk of age) and were significantly higher
than SFRs of CFA-treated or control NOD groups (n = 5 per group; P < 0.05). SFRs in CFA (triangular) or control (untreated; open circle) groups
continued to decrease during the follow-up period (*P < 0.05). Reproduced with permission from: [35].
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MSC therapy alone reduced inflammation, but there was
additional tissue repair and regeneration when adminis-
tered in conjunction with CFA.
Xu et al. [31] investigated the therapeutic effects of
allogeneic bone marrow-derived MSCs in both preventa-
tive and therapeutic interventions using NOD/Ltj mice
with Sjögren’s syndrome-like autoimmune disorders. As
SS symptoms in mice typically manifest around 7-8
weeks of age, preventative infusions of MSCs were given
at an age of 6 weeks while the treatment group received
MSC infusions at 16 weeks of age. MSC infusion signifi-
cantly decreased submandibular gland inflammation in
both preventative and treatment groups by supporting
Treg and Th2 differentiation while limiting Th17 and
Tfh responses. Additionally, preventative infusions of
MSCs resulted in sustained saliva flow rates; saliva flow
rates significantly increased after 2 weeks in the MSC
treatment group. These outcomes indicate that allogen-
eic MSCs were effective in both preventing and reducing
inflammatory responses as well as sustaining and restoring
salivary gland function in SS-like autoimmune mice [31].
Importantly, Xu et al. also conducted a clinical investiga-
tion in the efficacy of allogeneic MSC treatment in 24human patients with primary SS, including 11 with xeros-
tomia [31]. Allogeneic MSC infusions were tolerated well
by all 24 patients, with no adverse events reported either
during or post-MSC infusion. Furthermore, all patients
displayed symptom improvements after MSC treatment,
although the response time ranged from 2 weeks to
6 months. For the 11 patients with xerostomia, 2 weeks
after MSC treatment the unstimulated salivary flow rate
significantly increased; after 1 month, it exhibited a 2-
fold increase, and continued to rise on follow-up visits.
Stimulated salivary flow rate also significantly increased
at follow-up over the course of 12 months. Overall,
these findings demonstrate that the MSC treatment in
human patients was well tolerated, inhibited the inflam-
matory response, significantly increased salivary flow
rate, and improved SS disease symptoms, indicating that
allogeneic MSC treatment is a safe and effective therapy
for patients with SS and xerostomia.
MSC therapy for radiation damaged salivary gland
regeneration
Several groups explored the effects of MSCs on radiation-
induced damage to salivary glands [32-34]. Sumita et al.
[32] investigated the capacity of intravenously injected
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store function to the salivary gland of mice exposed to
head and neck irradiation. Salivary flow rate significantly
increased at 8 and 24 weeks post-radiation in MSC-
treated mice compared with untreated controls: at 8 weeks
it was 2-fold higher, and had increased to a level compar-
able to that of normal mice. Compared to untreated con-
trols, MSC-treated mice displayed significantly reduced
cell apoptosis, a 2.5-fold increase in blood vessel percent,
a significantly increased number of proliferative salivary
epithelial cells, and significantly higher regeneration of ac-
inar cells [32]. Moreover, transplanted MSC differentiation
into salivary epithelial cells was observed. These results in-
dicate that MSCs have vasculogeneic and paracrine effects
that increase acinar cell proliferation and inhibit cell apop-
tosis, as well as the capacity to directly differentiate into
salivary epithelial cells. Thus, MSCs can restore gland
function and regenerate radiation-damaged salivary tissue.
Lin et al. [33] studied the therapeutic potential of MSCs
for salivary gland regeneration both in vitro and in vivo.
After 3 weeks of co-culture (MSCs and acinar cells), about
half of the MSCs had differentiated into acinar-like cells,
demonstrating MSC differentiation capacity in vitro. Both
MSCs and differentiated acinar-like cells significantly in-
creased saliva production, salivary gland weight, and body
weight when transplanted into radiation-treated mice;
these systemic and local effects indicate salivary gland re-
generation. Moreover, after 43 days, transplanted MSCs
were found to be integrated into the salivary gland and
transdifferentiated into acinar-like cells. Therefore, trans-
plantation of either MSCs or differentiated acinar-like
cells may aid regeneration and restore functional salivary
glands.
Lim et al. [34] investigated the effects of direct trans-
plantation of highly homogeneous MSCs on salivary
gland regeneration and functional restoration in mice
after neck radiation. Irradiated mice that received MSCs
showed significant increase in saliva flow rate and im-
provement in salivary gland weight compared to irradi-
ated control mice that only received a PBS injection;
moreover, the MSC treatment group had fewer apoptotic
cells, higher numbers of functional acinar cells, and an
increase in blood microvessel density. These results indi-
cate that transplanted MSCs are capable of grafting into
radiation-damaged salivary glands and preserving saliv-
ary gland function while reducing apoptosis and increas-
ing microvessel density.
Adipose-derived MSC therapy for radiation damaged
salivary gland regeneration
Two studies explored the use of adipose-derived MSCs
(AdMSCs) for salivary gland regeneration as these cells
are readily available and are known to contribute to angio-
genesis and to secrete multiple cytokines and growthfactors [36,37]. Kojima et al. [36] employed radiation to in-
duce hyposalivation in mice in order to probe the regen-
erative potential of adipose-derived stromal cells (ADSCs)
to restore salivary gland function. After percutaneous ad-
ministration of ADSCs to the submandibular glands of ir-
radiated mice, they found that saliva flow rate was
significantly improved, recovering to about 75% of that
found in normal mice after 5 weeks, while mice in the
sham treatment group remained hyposalivary. The ADSC
treatment group also tended to have more acinar cells,
blood endothelial cell recovery to levels comparable to
those of normal mice, and alleviation of the severe inflam-
matory infiltration found in the sham group. Furthermore,
ADSC treatment displayed significant increases in angio-
genesis enzymes and growth factors critical to salivary
gland regeneration. These findings indicate that ADSC
treatment can restore salivary gland function after radi-
ation damage through paracrine effects, restoration of
blood flow, and differentiation of ADSCs into endothelial
cells. However, this study is limited by the fact that no
ADSCs were observed to differentiate into acinar cells
which affect hyposalivation directly.
Lim et al. [37] investigated the effects of multiple infu-
sions of human adipose-derived MSCs (hAdMSCs) on sal-
ivary gland function in radiation damaged mice. 6 hours
after the dose of radiation, mice were intravenously in-
fused with hAdMSCs; infusions were performed again
once a week for 3 consecutive weeks thereafter. At
12 weeks post-radiation, treated mice showed less peri-
ductal and perivascular fibrosis, significantly reduced
numbers of apoptotic cells, and greater numbers of acinar
cells compared to the untreated group. Differentiation of
hAdMSCs into salivary gland cells was observed after
4 weeks in vivo as well as after co-culture in vitro with
salivary gland cells. Treatment with hAdMSCs also sig-
nificantly increased post-stimulation salivary flow rate
compared to untreated controls, promoted regeneration
of salivary gland cells, and provided protection against
radiation damage to cells. These results show that xeno-
geneic hAdMSCs can migrate through the bloodstream
to radiation-damaged salivary glands and promote func-
tional recovery, indicating that hAdMSCs have potential
for salivary gland restoration.
Human amniotic epithelial cells
Recently, much attention has been dedicated towards
the study of stem cells derived from placental tissues.
Many studies have reported the isolation and identifica-
tion of various pluripotent and broadly multipotent cell
types from umbilical cord blood, amniotic and chorionic
membranes, wharton’s jelly, and amniotic fluid [38-43].
In regard to the use of placental derived stem cells for
salivary gland regeneration, only two studies have been
done. In both studies, human amniotic epithelial cells
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nar cell regeneration [44,45].
hAECs are typically derived from the top-most layer of
the amniotic membrane via trypsinization of the mem-
brane following its collection during cesarean section.
Human amniotic epithelial cells are similar to epithelial
cells in the sense that they express common epithelial
markers such as cytokeratin 7 (CK7) and are negative
for CD44. However, unlike adult epithelial cells, these
cells have been demonstrated to express characteristic
markers of pluripotent stem cells such as stage specific
embryonic antigen-4 (SSEA4), octamer binding protein-
4 (oct-4), and Nanog [46]. Additionally, these cells have
a stem-cell like character and demonstrate the capability
to differentiate into a multitude of different lineages
from all three embryonic germ layers such as osteocytes,
adipocytes, neurons, hepatocytes, cardiomyocytes, and
pancreatic cells [47,48]. In the following studies, hAECs
were differentiated into functional acinar cells by utiliz-
ing different methods.
In the first study, hAECs were isolated and co-cultured
with submandibular salivary gland acinar cells of sqrague
dawley rats using a double-chamber system for 1–2 weeks
to induce their differentiation into salivary gland acinar
cells [44]. At each time point, cells were analyzed with im-
munohistochemistry and RT-PCR for a variety of human
and salivary gland specific factors. At the initial time point,
hAECs were weakly positive for alpha amylase, however,
expression increased 3.3 fold after 1 week and 6.6 fold
after 2 weeks of co-culture with rat salivary gland acinar
cells. Additionally, immunofluorescent staining confirmed
cytokeratin 19 (CK19) expression in hAECs after 2 weeks.
Both the immunofluorescent and RT-PCR analyses con-
firmed the capability of hAECs to trans-differentiate into
salivary gland acinar cells.
In a separate study, isolated hAECs were injected into
the irradiated glands of mice [45]. The glands were ana-
lyzed after 14 and 30 days using H&E and immunofluor-
escent staining. H&E staining revealed that irradiated
glands treated with hAEC injections more closely re-
sembled the histological structure of the non-irradiated
controls. Immunofluorescent staining confirmed the ex-
pression of MAB1281 as well as CK7, cytokeratin 14
(CK14), and amylase. The presence of MAB1281 and
CK7/CK14 after 30 days demonstrated that the salivary
glands were still inhabited by human cells. These cells
expressed salivary gland acinar cell specific markers in-
dicate that they had trans-differentiated into saliva pro-
ducing cells. Additionally, the salivary flow rate was also
assessed. For irradiated salivary glands treated with
hAEC injection, salivary flow rate at 30 days was re-
stored to 48% of the non-irradiated controls. Overall,
the study determined that intra-glandularly injected
hAECs were capable of differentiating into acinar cellsand restoring saliva production in irradiated mice,
highlighting the potential of hAECs to serve as a stem
cell source for salivary gland regeneration in clinical
applications.
Recent bioengineering approaches
One of the most common treatments for hyposalivation
is oral administration of drugs for the stimulation of sal-
iva flow. Muscarinic receptor agonists, such as pilocar-
pine and cevimeline, have been widely used as orally
administered drugs for hyposalivation treatment [49-51].
However, this oral administration may cause a variety of
side effects including nausea, diarrhea, dyspepsia, ab-
dominal pain, dizziness, rhinitis, and hypertension [52].
The side effects may lead some patients to become un-
comfortable with therapy and to return to palliative care.
Thus, a controlled release of drugs at the salivary gland
was considered to reduce the drug dosage which attenu-
ates the occurrence of side effects [53]. Controlled drug
release systems have been developed by utilizing various
polymers such as hydrogels, [54] polymer based micro-
chips, [55,56] nanoshells, [57,58] and microfluidics; [58]
these systems enable drug supply to the target area with
a desired release pattern. Commercial polymer hydrogels
for a controlled release of pilocarpine have already been
clinically tested in patients with Sjögren’s syndrome [53].
The pilocarpine-containing polymer hydrogel was placed
into the buccal sulcus of the patients and it released in
excess of 85% of loaded pilocarpine over 3 hours. Saliva
and tear production were generally increased, and oral
and ocular comfort scores assessed by visual linear
analogue scale were also generally improved [53]. Poly
(lactic-co-glycolic acid) (PLGA) microparticles were also
developed for the controlled release of drugs in the saliv-
ary gland and evaluated for biocompatibility with the
parotid tissue [59]. These controlled drug delivery sys-
tems potentially provide better management of salivary
gland hyposalivation while having less adverse drug ef-
fects. However, the consistency of drug release kinetics,
specific targeting, and the design and shape of drug car-
rier should be further verified for the effective treatment
of hyposalivation. In addition, the severity of salivary
hypofunction may be varied between patients, and pa-
tients with the most advanced stage may have little saliv-
ary tissue left [53]. Thus, the extent of salivary gland
damage in each patient should also be carefully consid-
ered to determine the most effective drug therapy.
Gene delivery approach has also been considered as a
potential therapeutic treatment for hyposalivation. Salivary
glands have several advantages for clinical gene delivery
[60]. Salivary glands are easily accessible for the treat-
ment by gene-delivering vectors in a less-invasive
manner. In addition, the gene-delivering vectors are
well-encapsulated in the human salivary gland, which
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[60]. We can also easily assess important physiological
processes of salivary gland tissue, and it is not for life-
threatening if severe unwanted complication occurs.
General gene delivery techniques to major salivary
glands are based on cannulation of parotid or subman-
dibular ducts, which does not require local anesthesia
and are readily injectable in the mouth [60]. Gene trans-
fer into cells can be achieved using viral and non-viral
vectors. Viral vectors are currently the most efficient
vectors for gene transfer, but there are some safety con-
cerns when using viral vectors; the risk of generating in-
sertional mutagenesis, replication-competent virus, and
immune responses may limit the clinical use of viral
vectors [61-63]. On the contrary, non-viral vectors have
less safety issues, but they show inefficiency of gene
transfer in mammalian cells. For salivary glands, non-
viral vectors are rarely used, whereas adenovirus type 5
(Ad5) and adeno-associated virus type 2 (AAV2) vectors
are most often applied [60]. Ad5 vectors efficiently
transduce salivary gland epithelial cells in various ani-
mals, such as mice, rats, and non-human primates, and
generate the expression of the delivered gene in high
levels, although they are transient due to a considerable
immune response [64]. In contrast, AAV2-delivered gene
expression remains much longer because they generate
less host immune response, thus AAV2 vectors can be
useful for studies requiring long-term expression [65].
However, AAV2 vector construction is more difficult than
Ad5 vector creation, so we need to further understand its
biology for convenient application [60]. Various salivary
gene delivery applications for hyposalivation treatment
have been reported; their applications in animal models
demonstrated the great potential for hyposalivation treat-
ment. Human aquaporin-1 (hAQP1) gene was transferred
to pigs and rats for repair of irradiated salivary glands
[66,67]. In addition, manganese superoxide dismutase-
plasmid/liposome (MnSOD-PL), basic fibroblast growth
factor (bFGF), and vascular endothelial growth factor
(VEGF) genes were transferred to mice for the prevention
of radiation damage of salivary glands [68,69]. For the
treatment of Sjögren’s syndrome, Interleukin-10 (IL-10),
interleukin-17 (IL-17), and vasoactive intestinal peptide
(VIP) genes were also transferred to mice [70-72]. Among
various delivery genes, hAQP1 gene encodes a water
channel membrane protein which stimulates rapid water
movement in response to an osmotic gradient. Thus,
transferring hAQP1 gene to duct cells in radiation dam-
aged salivary glands is expected to induce fluid secretion
by providing stimulated water permeability pathways in
duct cells [60,66,73]. A human clinical trial of hAQP1
gene delivery to the parotid glands of patients with radi-
ation induced hyposalivation is ongoing [73,74]. In this
study, it was confirmed that the spread of treated Ad5-hAQP1 vector was limited by the gland capsule [74]. The
patients apparently had a latent Ad5 infection in the tar-
geted parotid gland which was activated after hAQP1 gene
delivery. However, no virus or vector was detected in the
patients’ serum [74]. Based on previous studies, gene de-
livery approaches can provide valuable translational possi-
bilities for hyposalivation treatment. In order to provide
better clinical availability, the long-term safety of gene de-
livering vectors and appropriate delivery genes should be
further identified.
Recently, bone marrow-derived cells (BMC) mobilization
by cytokine stimulation has also been reported for hyposa-
livation treatment [75,76]. The subcutaneous injection
of granulocyte colony stimulating factor (G-CSF) mobi-
lized BMCs to the blood stream, which resulted in BMC
migration to irradiated mouse salivary glands leading to
improved morphology and function [75]. It was sug-
gested that the BMC-mediated paracrine stimulation
could enhance the glandular regeneration process. In
addition, the combination treatment of G-CSF, FMS-
like tyrosine kinase-3 ligand (Flt-3 L), and stem cell factor
(SCF) further increased the number of different types of
mobilized BMC; this treatment not only reduced the
radiation-induced hyposalivation but also ameliorated
the submandibular vascular damage through BMC-
derived neovascularization [76]. This approach suggests
clinical applicability for the use of BMC mobilization to
improve radiation-induced damage. To utilize this treat-
ment most effectively, the molecular mechanisms be-
hind the observed protection and long-term duration
must be further explored.
Various current approaches including the delivery of
stem cell and therapeutic molecules such as drugs, genes,
and cytokines, hold great promise to overcome the chal-
lenge of hyposalivation; however, they provide only partial
restoration of the damaged salivary gland and its function.
Thus, to achieve the complete functional replacement
of lost or damaged tissue, a novel bioengineering ap-
proach reconstructing a fully functional organ was pro-
posed [15,77,78]. This approach, called the “organ germ
method”, demonstrated the regeneration of fully func-
tional salivary glands in mice, which was induced by recip-
rocal epithelial and mesenchymal interactions through the
engraftment of a bioengineered salivary gland germ. The
bioengineered gland germs were constructed with epithe-
lial and mesenchymal single cells obtained from each
gland germ at mouse embryonic day 13.5-14.5; they then
developed into a mature gland through acinar formations
(Figure 4) [78]. The bioengineered submandibular gland
showed the production of sufficient saliva in response
to pilocarpine administration and gustatory stimulation
by citrate and the recovery of swallowing in a salivary
gland defective mouse model [78]. The organ germ
method provides a proof-of-concept of regeneration by
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hyposalivation. However, to realize the clinical practice
of this method, the identification of an appropriate cell
source for a bioengineered salivary gland germ should
be established [15]. Thus, it will be necessary to identify
somatic and other tissue-derived stem cell populations
from the patient that have the capability to reproduce
salivary gland organogenesis via epithelial-mesenchymal
interactions.Conclusion
Many bioengineering and adult stem cell therapies for the
treatment of hyposalivation are currently being developed
and investigated. Most of these treatments rely on the
utilization of allogeneic, adult derived stem cells. While
many of these therapies are promising, there are still
shortcomings that need to be addressed in the future. For
example, the role that allogeneic stem cells play in regen-
eration has been shown to be transient in nature [79]. In
this regard, it is suggested that allogeneic stem cells play
two main roles in regeneration. First, allogeneic stem cells
have immunosuppressive properties that allow them to
quell inflammatory responses to encourage more robust
healing. Secondly, they serve to recruit endogenous stem
cell populations to the site of injury and encourage regen-
eration [80-82]. However, in an environment where no en-
dogenous stem cell population is present (such as in the
case of radiation induced xerostomia) and implanted stem
cells are intended to serve as a functional replacement,
this may be problematic. It has been reasonably deter-
mined that the short-lived nature of allogeneic stem cells
is a by-product of the host immune response [83,84]. Con-
sidering this fact, several strategies have been proposed inFigure 4 Generation and transplantation of a bioengineered salivary
gland germ, tissues, dissociated cells, and the bioengineered submandibula
200 μm. B. Schematic presentation of the transplantation procedure using
bioengineered salivary gland germ. Reproduced with permission from: [78]order to protect donor allogeneic cells from up-take by re-
cipient immune responses.
The first strategy involves the use of immunoprotec-
tive biomaterials intended to isolate the donor stem cells
from the recipient’s innate immune cells, yet, allow the
diffusion of essential nutrients and oxygen necessary to
maintain cellular viability. A few research groups have
investigated the use of various biomaterials and configu-
rations for this purpose [85-87]. A prominent example
of this strategy in commercial development is the Encap-
tra system, which was developed for Viacyte’s allogeneic
cellular therapy for the treatment of diabetes, PEC-01.
This system consists of a pouch made up of three layers
of polymeric meshing with decreasing porosity, with the
innermost layer exhibiting the smallest pore size. The
porosity of the outermost layers are amenable to the es-
tablishment of vascular networks, while the innermost
layer prevents invasion by host immune cells, allowing
the diffusion of oxygen and nutrients to the encapsu-
lated therapeutic cell populations while isolating them
from immunological attack. A second strategy, which
may be used in conjunction with an immunoprotective
barrier, is to induce the overexpression of various anti-
inflammatory cytokines by therapeutic cell populations.
In one such study, BMSCs were encouraged to overex-
press the anti-inflammatory cytokine IL-10 using an
mRNA transfection technology [88]. This serves to pro-
tect the allogeneic stem cells from the recipient’s im-
mune response by suppressing the host’s immunological
cell activity, thus allowing them to carry out their thera-
peutic function more efficiently.
An alternative solution to the problem of donor cell
destruction is to utilize autologous cell populations cap-
able of forming salivary gland acinar cells. In this sense,gland germ. A. Phase contrast images of the ED 13.5 submandibular
r gland germ. E, epithelial cells; M mesenchymal cells. Scale bar,
the interepithelial tissue connecting plastic method with the
.
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potent stem cells (iPSCs). IPSCs, which are derived from
adult somatic cells of the patient via reprogramming to
express a subset of pluripotency genes and induce an
embryonic-like state, would be an ideal candidate for
autologous cellular therapy due to enhanced potency
and immunological compatibility [89]. However, due to
current safety concerns and associated regulatory bar-
riers, the adoption of this technology is much more dis-
tant [90].
With regard to the differentiation of various stem cell
populations, a majority of studies induce differentiation
either by co-culture with isolated salivary gland cells or
by injection into the salivary glands of mice. In the fu-
ture, it would be beneficial to identify and utilize spe-
cific growth factors to create an induction media to ease
the study of various stem cell types in-vitro and allow
for consistency in deriving acinar-like salivary gland
cells. Preliminary work has been performed to elucidate
some of the conditions necessary to induce the differenti-
ation of progenitor cell populations into salivary gland
acinar-like cells. For example, one study found that TGF-
b1 inhibited the expression of acinar cell associated genes
from mesenchyme progenitors while TGF-bR1 inhibitor
increased their expression [91]. Further work must be
done in order to ascertain the specific growth factors ne-
cessary to create a standard induction media.
This paper is intended to provide an up to date review
on the current status of salivary gland regeneration for the
treatment of xerostomia induced hyposalivation. Over-
all, it has been demonstrated that tissue engineering ap-
proaches utilizing stem cells and biomaterials have the
capability to become a viable means to achieve mean-
ingful salivary gland regeneration. However, while pre-
liminary in-vitro, animal, and human clinical studies
have yielded promising results, it is clear that additional
research is needed before salivary gland regeneration
becomes a widespread therapeutic and clinical option.
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